Table 2.
Outcomes and their measures during phases 2 and 3 of the Excellence in Disability Prevention Integrated across NTDs (EnDPoINT) study
| Type of outcomes | Specific outcome | Outcome measures |
| Implementation outcomes | Adoption | Qualitatively (KIIs/FGDs, observation) |
| Feasibility | Qualitatively (KIIs/FGDs, observation); cost of training/interventions; number of cases identified, assessed and treated | |
| Acceptability (by providers and affected persons) | Qualitatively (KIIs/FGDs, observation) | |
| Appropriateness | Qualitatively (KIIs/FGDs, observation) | |
| Fidelity | Qualitatively (KIIs/FGDs, observation) | |
| Readiness for scale-up | Qualitatively (KIIs/FGDs, observation) | |
| Economic characteristics of study participants | Purposely designed questionnaire | |
| Resource use associated with delivering the care package | Project financial records and interviews with project manager(s) | |
| Effectiveness (patient level) | MMDP assessment | Swelling circumference (physical measurements); frequency of acute attacks (patient self-report); stage/grade of affected limb (physical assessment); signs of infection (physical assessment); wounds (physical assessment); nodules (physical assessment) |
| Depression | Patient Health Questionnaire 9 | |
| Suicidal ideation and action | CIDI questions | |
| Alcohol use | Fast Alcohol Screening Test | |
| Quality of life | Dermatology Life Quality Index | |
| Disability | WHO Disability Assessment Schedule 2.0 | |
| Internalised stigma | Internalised stigma related to lymphoedema | |
| Discrimination | Discrimination and Stigma Scale 12 | |
| Social support | Social Support Scale (OSLO-3) | |
| Happiness | Happiness index | |
| Use of primary care/cost | Purposely designed questionnaire | |
| Use of hospital care/cost | Purposely designed questionnaire | |
| Use of medication/cost | Purposely designed questionnaire | |
| Personal expenses | Purposely designed questionnaire | |
| Days off work due to illness/cost | Purposely designed questionnaire | |
| Effectiveness (community level) | Coverage | Number of cases identified, assessed and treated; proportion of cases detected who are then treated; number of affected persons reached with MMDP supplies; number of affected persons who have received mental healthcare; contact coverage |
| KAP lymphoedema | Purposely designed questionnaire | |
| Social distance | Social Distance Scale (SDS) | |
| Effectiveness (facility level) | KAP lymphoedema | Purposely designed questionnaire |
| KAP mental health | Purposely designed questionnaire | |
| Other outcomes | Suitability of training and training materials | Qualitatively (KIIs/FGDs, observation) |
| Satisfaction with training | Purposely designed questionnaire; qualitatively (KIIs/FGDs, observation) |
FGDs, focus group discussions; KAP, knowledge, attitudes and practice; KIIs, key informant interviews; MMDP, morbidity management and disability prevention.